Semaglutide 5mg (Single Vial)

GLP-1 Receptor Agonist | Weekly Injectable for Weight Management

Overview:

Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes and now widely used in medically guided weight loss and metabolic optimization protocols. By mimicking the natural hormone GLP-1, it helps regulate blood sugar, reduce appetite, and delay gastric emptying — resulting in sustained fat loss, improved insulin sensitivity, and enhanced satiety.

This product contains Semaglutide in lyophilized (freeze-dried) powder form, requiring reconstitution before use.

Product Details

GLP-1 Receptor Agonist | Weekly Injectable for Weight Management

Overview:

Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes and now widely used in medically guided weight loss and metabolic optimization protocols. By mimicking the natural hormone GLP-1, it helps regulate blood sugar, reduce appetite, and delay gastric emptying — resulting in sustained fat loss, improved insulin sensitivity, and enhanced satiety.

This product contains Semaglutide in lyophilized (freeze-dried) powder form, requiring reconstitution before use.

Why Choose Semaglutide 5mg (Single Vial)?

Semaglutide is one of the most widely studied GLP-1 receptor agonists, offering consistent, predictable results when used responsibly.

Its once-weekly dosing, strong appetite regulation, and metabolic benefits make it a reliable choice for structured weight management protocols.

Key Benefits

• Supports significant weight loss over 8–24 weeks

• Reduces appetite and cravings

• Improves blood sugar control and metabolic health

• Convenient once-weekly subcutaneous injection

Reconstitution Instructions

• Reconstitute using Bacteriostatic Water (BAC)

• Add your desired amount of BAC to the vial based on your preferred concentration (e.g., 1mL for a 5mg vial = 5mg/mL)

• Gently swirl until fully dissolved — do not shake

• Store reconstituted solution refrigerated (2–8°C) and use within 28 days

Typical Dosing Guidelines

• Start at 0.25mg weekly, then gradually increase to 0.5mg–2.0mg/week based on tolerance and goals

• Administer via subcutaneous injection in the abdomen, thigh, or upper arm

• Typical use spans 8–24 weeks, depending on progress

Monitoring & Considerations:

• Common side effects: Mild nausea, fatigue, appetite suppression, occasional GI discomfort

• Monitor hydration, blood sugar, and GI response

• Not for individuals with a history of medullary thyroid carcinoma (MTC) or MEN2 syndromes

Note